Ly6C
high monocytes migrate to inflamed sites, orchestrating the inflammatory reaction, and respond to endothelial activation by infiltrating lesions, which become atherosclerotic. 7, 8 Ly6C low monocytes are the noninflammatory subtype. They display high levels of CX3CR1 and CD11c expression but low levels of CCR2 expression (Ly6C   low   CCR2   low   CX3CR1   high   CD11c   high   CD115   high   ) , and their primary function is repair. 5 They patrol the vasculature, infiltrating atherosclerotic lesions less frequently than Ly6C high monocytes, and their role in the generation of atherosclerotic plaques remains unclear. 2, 3, 6 See accompanying editorial on page 173
Hypercholesterolemia induces monocytosis, with a profound expansion, principally of the not only circulating Ly6C high cells, 11 and a single microRNA, miR146a, controls the amplitude of the Ly6C high monocyte response to inflammatory challenge, without affecting Ly6C low monocytes. 12 By contrast, an absence of the transcription factor Nr4a1 results in lower levels of survival for Ly6C low monocytes. 13 © 2016 American Heart Association, Inc. Map3k8 participates in intracellular signaling pathways involving Toll-like receptors, interleukin (IL)-1R, tumor necrosis factor-αR, NOD-2 (nucleotide-binding oligomerization domain-like 2R), and adiponectinR. [14] [15] [16] [17] [18] [19] The signaling function of Map3k8 has been studied in most detail in macrophages and dendritic cells. After the Toll-like receptor-mediated activation of macrophages, Map3k8 mediates MKK1/2-ERK1/2 activation and exerts fine control over the activation state of other signaling transduction pathways, such as those mediated by c-Jun N-terminal kinase and Akt-p70-S6k. 20, 21 Map3k8 plays a unique role in the production of inflammatory mediators in vivo, 14, 19, 22 modifying the activation state of macrophages, monocytes, astrocytes, dendritic cells, stellate cells, myofibroblasts, and plasma cells, and no other protein can replace Map3k8 in this role. 16, 18, [23] [24] [25] [26] [27] [28] [29] We show here that, in atherogenic conditions, Map3k8 is required to maintain the number of monocytes, by limiting apoptosis. Furthermore, the strong expression of CCR2 on Ly6C high monocytes and the firm adhesion of leukocytes to arterioles and venules in vivo are dependent on Map3k8. These data explain the smaller aortic lesions in Map3K8 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Figure 1A ). Map3k8 deficiency had no effect on the numbers of other hematopoietic cells, such as neutrophils, and lymphocytes, in the blood, spleen, or BM ( Figure II in the online-only Data Supplement).
Results

Map3k8 Modulates Monocytosis in
Two main subsets of circulating monocytes have been described in mice on the basis of Ly6C and CD11c expression. [3] [4] [5] Hypercholesterolemia mostly increases the frequency of Ly6C high monocytes but also increases the frequency of CD11c high monocytes in the blood of atherogenic mice. [7] [8] [9] [10] Map3k8 deficiency in ApoE −/− mice fed an HFD significantly decreased the number of Ly6C 
Deficiency of Map3k8 Increases Apoptosis and Decreases Nr4a1 Expression in Circulating Monocytes of HFD-Fed ApoE −/− Mice
We investigated the reason for the smaller number of circulating monocytes in Map3k8-deficient ApoE −/− mice fed an HFD, and the percentage of apoptosis was determined in these cells. Map3k8 deficiency increased apoptosis in both monocyte subsets, Ly6C high CD11c low and Ly6C low CD11c high , and this increase was greater for Ly6C low CD11c high monocytes (Figure 2A ). In vitro experiments indicated that, 2 to 4 hours after incubation with lipopolysaccharide plus cycloheximide, the percentage of apoptosis was higher for BM-derived We then investigated the role of Map3k8 in the expression of factors known to modify the survival or amplification of both types of monocytes, by purifying both circulating monocyte subsets and subjecting them to reverse transcriptionquantitative PCR analysis. Levels of miR-146a tended to be -qPCR; n=6) . The mean±SEM is shown. One-way ANOVA with Bonferroni correction was used to compare all pairs of columns between groups. We show only the statistical significance of differences between the different cell types analyzed from Map3k8 +/+ ApoE −/− and from Map3k8 −/− ApoE −/− mice, and between the different experimental conditions for mice with and without MAP3K8. B, Isolated splenocytes from mice described in A were subjected to RT-qPCR analysis, and the mRNA levels of the indicated genes were determined (n=7). Two-tailed Student t tests were used for comparisons between 2 groups. A and B, *P<0.05, **P<0.01, ***P<0.001. Arg indicates arginase; COX, cyclooxygenase; HOX, heme oxygenase; INF, interferon; KC, chemokine (C-X-C motif) ligand 1; NOS, nitric oxide synthase; and TNF, tumor necrosis factor. Figure 2B ). Accordingly, Nr4a1 protein levels were also much lower in both monocyte subsets ( Figure 2C ). Map3k8 was also found to control the expression of Nr4a1 in lipopolysaccharide-stimulated BM-derived macrophages ( Figure V in the online-only Data Supplement).
Map3k8 Modifies the Expression of Chemokines and Cytokines in Peritoneal Macrophages and Splenocytes of ApoE −/− Mice Fed an HFD
Nr4a1 −/− macrophages are polarized toward an M1 phenotype. 31 We investigated the role of Map3k8 in the polarization of peritoneal ApoE −/− macrophages in response to an M1 (lipopolysaccharide) or M2 (IL-4, IL-10, and plus IL-13) stimulus. In response to lipopolysaccharide, Map3k8 deficiency decreased the mRNA expression of inflammatory mediators, such as tumor necrosis factor-α, IL-1β, IL-6, and chemokine (C-X-C motif) ligand markers nitric oxide synthase 2 and IL-12p40, but decreased cyclooxygenase-2 mRNA levels ( Figure 3A ). Map3k8 deficiency decreased the expression of the M2 marker IL-10 independently of the M1 or M2 stimulus. In response to IL-4, IL-10, and plus IL-13, Map3k8 deficiency decreased mRNA levels for the M2 marker arginase 1 but not for heme oxygenase-1 ( Figure 3A) . We also assessed the expression of chemokines and cytokines in splenocytes from Map3k8 +/+ ApoE −/− and Map3k8 −/− ApoE −/− mice fed an HFD. Map3k8 depletion decreased mRNA levels for the proinflammatory cytokines tumor necrosis factor-α and IL-1β, but increased mRNA levels for interferon-γ and IL-12p40. However, it had no effect on mRNA levels for IL-6 and IFN-γ-inducible protein-10. Full expression of IL-10 and of the chemokines chemokine (C-X-C motif) ligand 1 and chemokine (C-C motif) ligand 2 at the mRNA level was dependent on Map3k8, but it partly repressed the expression of chemokine (C-C motif) ligand 5 ( Figure 3B ). Figure 4A ). Map3k8 deficiency also decreased CCR2 mRNA levels to a similar extent in this subset of monocytes ( Figure 4B ). The expression of other membrane proteins involved in cell adhesion, such as CX3CR1, Mac-1, CD11a, CD62L, CD43, CD49D, and CD162, was not affected by Map3k8 deficiency in either of the monocyte subsets ( Figure VI in the online-only Data Supplement).
Map3k8 Modulates CCR2 Expression
CCR2 plays a key role in recruiting Ly6C Figure  4C ). These Map3k8 −/− cells recruited to the peritoneum also lacked CCR2 expression ( Figure 4D ). To note, Map3k8 deficiency did not regulate the migration of Map3k8 CCR2 −/− mice display poor leukocyte adhesion to the microvascular endothelium and low levels of monocyte extravasation at the inflamed site. 33, 34 Intravital microscopy within the cremasteric microcirculation of Map3k8 +/+ ApoE −/− and Map3k8 −/− ApoE −/− mice fed the HFD indicated that Map3k8 deficiency was associated with lower levels of leukocyte adhesion to both arterioles and venules and with a greater rolling velocity of these cells ( Figure 5 ).
Map3k8 Deficiency in BM Cells Results in Smaller Aortic Lesions in ApoE −/− Mice Fed an HFD
The pathological recruitment of monocytes to the arterial wall and the subsequent accumulation of lipids in monocytederived macrophages are key events in the formation of the aortic lesion. 1 We evaluated lesion size in the aortic root. 
Discussion
Map3k8 has been reported to influence inflammatory processes by modulating the function of various cells types, according to the nature of the threat. 14, 19 We report here that Map3k8 modulates the number of monocytes, key cells in the development of atherosclerosis, which is a chronic low-grade inflammatory 
CD115
high cell viability, and its absence triggers apoptosis.
13 Map3k8-deficient monocytes also lack Nr4a1 expression. The modulation of Nr4a1 expression by Map3k8 seems to have a greater effect in the presence of proinflammatory stimuli. Nr4a1-deficient macrophages polarize toward a proinflammatory phenotype. 31 The Map3k8 effect on macrophages activation is complex, is required for the expression of inflammatory mediators, and has the capacity to repress some M1 gene makers on M1 stimulation, but also down modulates the expression of some M2 gene makers in M2-stimulated ApoE −/− macrophages. fed an HFD, consistent with previous findings that the leukocytes of CCR2 −/− mice display lower levels of firm adhesion to the microvascular endothelium and lower levels of Ly6C high monocyte recruitment to atherosclerotic lesions and the peritoneum after thioglycolate injection. 7, 8, 10, 33 The weaker expression of CCR2 on circulating Map3k8 mice fed an HFD. Our findings show that Map3k8 deficiency reduces the atheroma in ApoE −/− mice fed an HFD. Map3k8 is a component of the Toll-like receptor and IL-1R intracellular signaling pathways. 14, 19 Various Toll-like receptors, IL-1R, and their common adaptors, such as MyD88, TRAM, and TRIF, together with IL-1β, contribute to atherogenesis (reviewed in 39, 40 ). Our findings suggest that Map3k8, which acts downstream from MyD88 and TRIF in intracellular signaling pathways, 14, 19, 22 is one of the components of the proatherogenic intracellular signaling pathways triggered by the activation of these receptors. The way in which these receptors and adaptors affect monocytes in atherogenesis has never before been studied.
Map3k8 plays an important role in innate and adaptive immunity and has been identified as a potentially interesting treatment target in various diseases with an inflammatory component, such as progressive myeloma, 29 squamous cell carcinoma and keratoacanthoma, 41 inflammatory nociception, 26 Crohn-like inflammatory bowel disease, 42 and Schistosoma mansoni infection. 43 We show here that Map3k8 deficiency limits early atherosclerosis through its effects on the number of monocytes and their function. Further studies are clearly required to evaluate the risk/benefit ratio of therapeutic Map3k8 blockade in this disease and its consequences in terms of monocyte state.
